Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Aug 06, 2024
Analysis of the Cleaning Sector: Recent Performance and Key Indicators

Analysis of the Cleaning Sector: Recent Performance and Key Indicators

Sector Performance Overview

The cleaning sector has exhibited a notable performance increase, experiencing a +4.71% rise over the past week. This performance surge reflects positive market sentiment and possibly increasing demand within the sector.

Key Tickers in the Cleaning Sector

The primary tickers in this sector include:

  • Kimberly-Clark (KMB)
  • Ecolab (ECL)
  • Clorox (CLX)

These companies are leading players in the cleaning industry, each with its unique strengths and market positions.

Market Capitalization Analysis

Overall Market Cap

The average market capitalization across the cleaning sector is $42.9 billion. However, the market cap for individual companies in this group varies significantly, ranging from $1.1 billion to $66 billion.

Top and Bottom Valuations

  • Ecolab (ECL) holds the highest valuation at $66 billion.
  • Heritage-Crystal Clean (HCCI), though not a primary ticker, is noted as the lowest valued company at $1.1 billion.

This wide range in market capitalization indicates a mix of large, well-established firms and smaller, potentially more agile companies within the sector.

Price Growth Analysis

Weekly, Monthly, and Quarterly Trends

  • Weekly Price Growth: The average price growth across all stocks in the cleaning sector was 4.7% over the past week.
  • Monthly Price Growth: The sector saw a 2.47% average price growth over the past month.
  • Quarterly Price Growth: Over the last quarter, the sector experienced a robust 9.59% growth.

Notable Movers

  • Clorox (CLX) achieved the highest weekly price growth at 6.56%.
  • Ecolab (ECL) experienced the most significant decline, with a -6.72% drop over the same period.

Recent notable news includes:

  • On July 31, 2024, Ecolab (ECL) saw a -7.24% decline, making it a top loser for the week.
  • On June 6, 2024, Ecolab (ECL) was a top weekly gainer with a +5.78% jump.
  • On June 5, 2024, Kimberly-Clark (KMB) also recorded significant gains, with a +6.38% increase.

Volume Trends

Volume Growth Analysis

  • Weekly Volume Growth: The average weekly volume growth across the cleaning sector was 60.78%.
  • Monthly Volume Growth: Over the past month, the sector experienced a significant 248.23% average volume growth.
  • Quarterly Volume Decline: Conversely, the average quarterly volume growth showed a decline of -12.9%.

A notable volume event:

  • On June 22, 2024, Clorox's stock volume spiked, resulting in a record-breaking daily growth of 241% compared to the 65-Day Volume Moving Average.

Technical Indicators and Stock Analysis

Kimberly-Clark (KMB)

Bollinger Bands Analysis:

  • Upward Trend Expectation: KMB's price is expected to rise as it breaks its lower Bollinger Band on July 30, 2024. Historically, in 29 out of 51 instances where KMB's price broke its lower Bollinger Band, it rose further in the following month (57% probability).
  • Current Price Position: The current price of $139.62 has crossed the resistance line at $134.30 and is trading between $152.22 (support) and $134.30 (resistance).

Ecolab (ECL)

RSI Oscillator Analysis:

  • Recovery from Oversold Territory: The RSI indicator for ECL moved out of oversold territory on July 31, 2024, signaling a potential upward trend. In 15 out of 21 similar cases, the stock moved higher, indicating a 71% probability of an upward move.
  • Current Price Position: The current price of $236.41 is above the highest resistance line of $157.71.

Clorox (CLX)

MACD Histogram Analysis:

  • Positive MACD Signal: The MACD histogram for CLX turned positive on August 2, 2024, historically leading to a rise in 35 out of 58 cases in the following month (60% probability).
  • Current Price Position: The current price of $142.91 has crossed the support line at $138.89, trading between $144.21 (resistance) and $138.89 (support).

In Summary:

The cleaning sector's recent performance highlights a sector in motion, with significant gains driven by key players like Kimberly-Clark, Ecolab, and Clorox. Market capitalization variations, notable price movements, and technical indicators provide insights into potential future trends. Investors should monitor these trends closely to capitalize on emerging opportunities within the sector.

Related Ticker: KMB, ECL, CLX

Contributor

Dem Sem's AvatarDem Sem|Expert

KMB's Stochastic Oscillator is remaining in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KMB's RSI Indicator exited the oversold zone, 15 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 42%.

Following a +1.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where KMB advanced for three days, in 128 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 42%.

KMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KMB as a result. In 47 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.

The Moving Average Convergence Divergence Histogram (MACD) for KMB turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 19 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 41%.

KMB moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KMB crossed bearishly below the 50-day moving average on September 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 44%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

The Aroon Indicator for KMB entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.762) is normal, around the industry mean (18.044). P/E Ratio (19.520) is within average values for comparable stocks, (43.673). Projected Growth (PEG Ratio) (2.018) is also within normal values, averaging (1.518). KMB has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.024). P/S Ratio (1.971) is also within normal values, averaging (1.931).

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. KMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL).

Industry description

Household/Personal Care companies sell products for home cleaning and/or personal hygiene and grooming purposes. Products of this industry include detergents, shampoos, soaps, cosmetics, fabric conditioners and infant care fragrances. Procter & Gamble, Unilever, Estee Lauder and Colgate-Palmolive are some of the biggest names in the business. A lot of the products become a necessary part of people’s daily routine, and therefore the industry is relatively less vulnerable to macroeconomic downturns. At the same time, product quality, consumer safety, and ease of use are extremely critical factors for a company to survive competition and earn recognition in this industry.

Market Cap

The average market capitalization across the Household/Personal Care Industry is 23.45B. The market cap for tickers in the group ranges from 60.48K to 346.15B. PG holds the highest valuation in this group at 346.15B. The lowest valued company is EOSS at 60.48K.

High and low price notable news

The average weekly price growth across all stocks in the Household/Personal Care Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 7%. ODD experienced the highest price growth at 11%, while TANH experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Household/Personal Care Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 43
Price Growth Rating: 57
SMR Rating: 72
Profit Risk Rating: 90
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
KMB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the manufacturing of paper based products and providing cleaning solutions

Industry HouseholdPersonalCare

Industry
Household Or Personal Care
Address
P.O. Box 619100
Phone
+1 972 281-1200
Employees
36000
Web
https://www.kimberly-clark.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.